26 related articles for article (PubMed ID: 1659842)
1. Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group.
Sulkes A; Smyth J; Sessa C; Dirix LY; Vermorken JB; Kaye S; Wanders J; Franklin H; LeBail N; Verweij J
Br J Cancer; 1994 Aug; 70(2):380-3. PubMed ID: 7914428
[TBL] [Abstract][Full Text] [Related]
2. Vinorelbine plus cisplatin versus cisplatin plus vindesine and mitomycin C in stage IIIB-IV non-small cell lung carcinoma: a prospective randomized study.
Gebbia V; Galetta D; Riccardi F; Gridelli C; Durini E; Borsellino N; Gebbia N; Valdesi M; Caruso M; Valenza R; Pezzella G; Colucci G;
Lung Cancer; 2002 Aug; 37(2):179-87. PubMed ID: 12140141
[TBL] [Abstract][Full Text] [Related]
3. Mitomycin C plus vindesine plus etoposide (MEV) versus mitomycin C plus vindesine plus cisplatin (MVP) in stage IV non-small-cell lung cancer: A phase III multicentre randomised trial. The "Gruppo Oncologico Centro-Sud-Isole' (G.O.C.S.I.).
Gridelli C; Perrone F; Palmeri S; D'Aprile M; Cognetti F; Rossi A; Gebbia V; Pepe R; Veltri E; Airoma G; Russo A; Incoronato P; Scinto AF; Palazzolo G; Natali M; Leonardi V; Gallo C; De Placido S; Bianco AR
Ann Oncol; 1996 Oct; 7(8):821-6. PubMed ID: 8922196
[TBL] [Abstract][Full Text] [Related]
4. A randomised clinical trial of vindesine plus cisplatin versus mitomycin plus vindesine and cisplatin in advanced non-small cell lung cancer.
Shinkai T; Eguchi K; Sasaki Y; Tamura T; Ohe Y; Kojima A; Oshita F; Saijo N
Eur J Cancer; 1991; 27(5):571-5. PubMed ID: 1647183
[TBL] [Abstract][Full Text] [Related]
5. Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small-cell lung cancer: results of the Toronto Phase II Trial.
Burkes RL; Ginsberg RJ; Shepherd FA; Blackstein ME; Goldberg ME; Waters PF; Patterson GA; Todd T; Pearson FG; Cooper JD
J Clin Oncol; 1992 Apr; 10(4):580-6. PubMed ID: 1312587
[TBL] [Abstract][Full Text] [Related]
6. Influence of pretreatment clinical characteristics on the response rate to mitomycin/vindesine/cisplatin (MVP) in unresectable non-small cell lung cancer. ATTIT (Association pour le Traitement des Tumeurs Intra-Thoraciques).
Riggi M; Ruffie P; Voisin S; Monnet I; de Cremoux H; Saltiel JC; Martin M; Vergne L; Huet J; Cvitkovic E
Eur J Cancer; 1991; 27(10):1238-42. PubMed ID: 1659842
[TBL] [Abstract][Full Text] [Related]
7. A randomized study of two vindesine plus cisplatin-containing regimens with the addition of mitomycin C or ifosfamide in patients with advanced non-small cell lung cancer.
Rosell R; Abad-Esteve A; Moreno I; Barnadas A; Carles J; Fernandez C; Ribelles N; Culubret M
Cancer; 1990 Apr; 65(8):1692-9. PubMed ID: 2156597
[TBL] [Abstract][Full Text] [Related]
8. Establishment of the standard regimen for non-small-cell lung cancer in Japan.
Masuda N
Oncology (Williston Park); 2001 Jan; 15(1 Suppl 1):13-8. PubMed ID: 11221016
[TBL] [Abstract][Full Text] [Related]
9. The case for mitomycin in non-small cell lung cancer.
Spain RC
Oncology; 1993 Apr; 50 Suppl 1():35-50. PubMed ID: 8387177
[TBL] [Abstract][Full Text] [Related]
10. [Combination of cisplatin-mitomycin-vindesine for inoperable, non-small-cell bronchial cancers. French study group in pneumo-cancerology].
Kleisbauer JP; Thomas P; Perol M; Taytard A; Poirier R; Collus MJ; Guerin JC; Vergnenegre A; Balmes P; Carles P
Rev Mal Respir; 1993; 10(4):307-12. PubMed ID: 7694331
[TBL] [Abstract][Full Text] [Related]
11. Non-small-cell lung cancer (NSCLC): chemotherapy in advanced disease. Our experience in ten years.
Gonzalez Baron M; Garcia Giron C; Zamora P; Garcia de Paredes ML; Feliu J; OrdoƱez A; Artal A; Garrido P; Chacon JI
Am J Clin Oncol; 1992 Feb; 15(1):23-8. PubMed ID: 1312769
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]